Results 151 to 160 of about 4,106 (260)

Effects of Corporate Greenwashing on Firm Value in China

open access: yesManagerial and Decision Economics, EarlyView.
ABSTRACT In response to rising public expectations for corporate environmental sustainability, instances of greenwashing have emerged as firms seek to alleviate regulatory pressure and mitigate reputational risks. This study examines the nonlinear economic consequences of corporate greenwashing by analyzing panel data from A‐share listed firms in China
Run Kong, Byungkwon Lim, Hyang Mi Choi
wiley   +1 more source

Long‐Term Institutional Ownership and Corporate Breakthrough Innovation: Evidence From the Perspective of Patient Capital

open access: yesManagerial and Decision Economics, EarlyView.
ABSTRACT This paper examines whether institutional ownership with different investment horizons is related to corporate breakthrough innovation, using panel data of Chinese A‐share listed firms from 2014 to 2023. Long‐term institutional ownership is positively and significantly associated with breakthrough innovation, while short‐term institutional ...
He Zeng   +3 more
wiley   +1 more source

Deep Brain Stimulation of the Posterior Subthalamic Area and the Subthalamic Nucleus in Tremor‐Dominant Parkinson's Disease: A Randomized, Crossover Trial

open access: yesMovement Disorders, EarlyView.
Abstract Background The posterior subthalamic area (PSA) is a familiarized target for Parkinson's disease (PD) in the lesioning era and has recently been reconsidered for deep brain stimulation (DBS). Objective The aim of this study was to compare the therapeutic efficacy of PSA versus subthalamic nucleus (STN) DBS in tremor‐dominant Parkinson's ...
Zhengyu Lin   +7 more
wiley   +1 more source

Oral GLP‐1RA TERN‐601 for Adults With Obesity/Overweight: Placebo‐Controlled, Multiple‐Ascending‐Dose, Phase 1 and 2 Studies

open access: yesObesity, EarlyView.
ABSTRACT Objective The safety, tolerability, pharmacokinetics, and efficacy of TERN‐601, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, were studied in Phase 1 and 2 clinical studies. Methods The Phase 1 (28‐day) and Phase 2 (12‐week), randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose studies ...
W. Timothy Garvey   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy